Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
4.930
+0.070 (1.44%)
At close: May 8, 2026, 4:00 PM EDT
4.950
+0.020 (0.41%)
After-hours: May 8, 2026, 7:06 PM EDT
Aclaris Therapeutics Employees
As of December 31, 2025, Aclaris Therapeutics had 73 total employees, including 69 full-time and 4 part-time employees. The number of employees increased by 9 or 14.06% compared to the previous year.
Employees
73
Change (1Y)
9
Growth (1Y)
14.06%
Revenue / Employee
$114,616
Profits / Employee
-$954,274
Market Cap
688.54M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 73 | 9 | 14.06% | 69 | 4 |
| Dec 31, 2024 | 64 | -27 | -29.67% | 61 | 3 |
| Dec 31, 2023 | 91 | -14 | -13.33% | 86 | 5 |
| Dec 31, 2022 | 105 | 28 | 36.36% | 100 | 5 |
| Dec 31, 2021 | 77 | 17 | 28.33% | 72 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Arvinas | 246 |
| CorMedix | 191 |
| Cabaletta Bio | 156 |
| Sutro Biopharma | 137 |
| Solid Biosciences | 121 |
| Alpha Tau Medical | 121 |
| Zevra Therapeutics | 61 |
ACRS News
- 2 days ago - Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference - GlobeNewsWire
- 3 days ago - Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c) - TheFly
- 3 days ago - Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c) - TheFly
- 3 days ago - Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - GlobeNewsWire
- 5 days ago - Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler - TheFly
- 5 days ago - Aclaris Therapeutics initiated with a Buy at Guggenheim - TheFly
- 5 days ago - Aclaris Therapeutics initiated with a Buy at Guggenheim - TheFly
- 11 days ago - Aclaris Therapeutics price target raised to $10 from $8 at Wedbush - TheFly